繁體中文
返回
- English
- 繁體中文
- 简体中文
- 深色
- 淺色
立即開戶
牛牛AI助理已提取核心訊息
Conduit Pharmaceuticals Inc. has issued a $5,737,500 convertible promissory note to A.G.P./Alliance Global Partners, due November 25, 2025. The note accrues 5.5% annual interest and is convertible to common stock at $0.10 per share, subject to adjustments and stockholder approval. Concurrently, Conduit amended its existing $2.65 million note with Nirland Limited, allowing conversion at the same rate.Both notes require stockholder approval for conversion and could potentially result in the issuance of up to 133 million new common shares combined. The company must file a resale registration statement for the new note within specified timeframes. If stockholder approval for the Nirland note conversion is not obtained by January 9, 2025, Conduit faces a $100,000 per day penalty.The notes are unsecured, governed by New York law, and were issued under exemptions from SEC registration requirements. Conduit may suspend the use of the prospectus for up to 60 total trading days in a 12-month period if needed to amend the registration statement.
Conduit Pharmaceuticals Inc. has issued a $5,737,500 convertible promissory note to A.G.P./Alliance Global Partners, due November 25, 2025. The note accrues 5.5% annual interest and is convertible to common stock at $0.10 per share, subject to adjustments and stockholder approval. Concurrently, Conduit amended its existing $2.65 million note with Nirland Limited, allowing conversion at the same rate.Both notes require stockholder approval for conversion and could potentially result in the issuance of up to 133 million new common shares combined. The company must file a resale registration statement for the new note within specified timeframes. If stockholder approval for the Nirland note conversion is not obtained by January 9, 2025, Conduit faces a $100,000 per day penalty.The notes are unsecured, governed by New York law, and were issued under exemptions from SEC registration requirements. Conduit may suspend the use of the prospectus for up to 60 total trading days in a 12-month period if needed to amend the registration statement.
Conduit Pharmaceuticals Inc. 向 A.G.P./Alliance Global Partners 發行了一張 5,737,500 美元的可轉換票據,到期日爲 2025 年 11 月 25 日。該票據按年利率 5.5% 計息,並可按每股 0.10 美元的價格轉換爲普通股,具體調整及需經股東批准。與此同時,Conduit 修改了與 Nirland Limited 現有的 265萬美元票據,使其允許以相同的匯率進行轉換。這兩張票據均需股東批准方可轉換,並可能導致最多 13300萬新普通股的發行。公司必須在規定的時間內爲新的票據提交轉售註冊聲明。如果在 2025 年 1 月...展開全部
Conduit Pharmaceuticals Inc. 向 A.G.P./Alliance Global Partners 發行了一張 5,737,500 美元的可轉換票據,到期日爲 2025 年 11 月 25 日。該票據按年利率 5.5% 計息,並可按每股 0.10 美元的價格轉換爲普通股,具體調整及需經股東批准。與此同時,Conduit 修改了與 Nirland Limited 現有的 265萬美元票據,使其允許以相同的匯率進行轉換。這兩張票據均需股東批准方可轉換,並可能導致最多 13300萬新普通股的發行。公司必須在規定的時間內爲新的票據提交轉售註冊聲明。如果在 2025 年 1 月 9 日之前未獲得 Nirland 票據轉換的股東批准,Conduit 將面臨每天 100,000 美元的罰款。這些票據是無擔保的,受紐約法律管轄,並根據 SEC 註冊要求的豁免發行。若需要修改註冊聲明,Conduit 可暫停使用招股說明書,累計最多 60 個交易日,限於 12 個月內。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
資訊熱榜
更新時間